Rani Therapeutics Holdings, Inc.
NASDAQ:RANIBiotechnology
-$0.04 today
- Market cap
- $52.19M
- Beta
- 0.76
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.16
Volume 0.23M
Average 1.15M
RANI EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Rani Therapeutics Holdings, Inc.NASDAQ: RANI
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$7.77M, compared with -$11.54M a year earlier. Trailing-twelve-month EBITDA was -$33.38M.
Context
- EBITDA amounted to 2275.5% of revenue in FY2025, down 2639.2 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of -$5.59M (+84.9%) for the fiscal year ending Dec 2026, a step up from the +26.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$7.77M+9.1% QoQ
- Last fiscal yearDec 2025
- -$37.16M+26.5% YoY
- LTMMar 2026
- -$33.38M+31.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +32.7% | +9.0% | -23.7 pp |
| 1 year | +26.5% | +84.9% | +58.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (37.16M) USD
- Year-over-year change
- +26.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (37.16M) | +26.5% |
| FY2024 | 2024-12-31 | (50.52M) | +18.5% |
| FY2023 | 2023-12-31 | (61.98M) | -0.5% |
| FY2022 | 2022-12-31 | (61.66M) | -18.4% |
| FY2021 | 2021-12-31 | (52.08M) | — |
EBITDA vs competitors
How RANI compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +31.6% is the highest of 9, against a peer median of -10.4%.
- EBITDA amounts to 1053.3% of revenue for RANI, versus a peer median of 1566.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$33.38M USD | +31.6% | — | 1053.3% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | -$37.68M USD | +23.9% | — | — |
| FY2025 | -€43.65M EUR | +7.0% | — | 1566.1% | |
| LTM Mar 2026 | -$43.73M USD | +9.5% | — | 8329.5% | |
| LTM Mar 2026 | -$61.36M USD | -27.4% | — | 3439.7% | |
| LTM Mar 2026 | -CHF 63.08M CHF | -8.3% | — | — | |
| LTM Mar 2026 | -$84.28M USD | -67.4% | — | — | |
| LTM Mar 2026 | -$117.46M USD | -66.2% | — | 339.9% | |
| LTM Mar 2026 | -$145.4M USD | -12.5% | — | 828.2% | |
| Peer median (excluding RANI) | — | -10.4% | — | 1566.1% | |
Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.72M | 0 | 0 | 1.03M | 1.63M |
| Cost of Revenue | 0 | 0 | 822K | 0 | 900K |
| Gross Profit | 2.72M | 0 | (822K) | 1.03M | 733K |
| Gross Margin | 100.0% | — | — | 100.0% | 44.9% |
| Research & Development | 26.48M | 36.61M | 39.62M | 26.68M | 20.21M |
| Selling, General & Admin | 27.83M | 26.84M | 26.48M | 23.95M | 19.74M |
| Operating Expenses | 54.32M | 63.45M | 65.28M | 54.34M | 39.04M |
| Depreciation & Amortization | 497K | 548K | 822K | 1.03M | 900K |
| EBITDA | (52.08M) | (61.66M) | (61.98M) | (50.52M) | (37.16M) |
| EBITDA Margin | -1917.0% | — | — | -4914.7% | -2275.5% |
| Operating Income | (51.6M) | (63.45M) | (66.1M) | (53.31M) | (38.31M) |
| Operating Margin | -1899.1% | — | — | -5186.2% | -2346.0% |
| Interest Income | 89K | 1.25M | 3.3M | 1.76M | 827K |
| Interest Expense | 466K | 1.07M | 5.09M | 5.03M | 2.89M |
| Other Income / Expenses | (1.45M) | 177K | (1.78M) | 23.3M | (2.64M) |
| Income Before Tax | (53.05M) | (63.27M) | (67.88M) | (30.02M) | (40.95M) |
| Pre-Tax Margin | -1952.4% | — | — | -2920.0% | -2507.7% |
| Income Tax Expense | 41K | 70K | 0 | 26.57M | 0 |
| Net Income | (8.33M) | (30.59M) | (33.97M) | (30.02M) | (29.67M) |
| Net Margin | -306.6% | — | — | -2920.0% | -1817.1% |
| EPS (Basic) | (0.42) | (1.28) | (1.33) | (1.05) | (0.45) |
| EPS (Diluted) | (0.42) | (1.28) | (1.33) | (1.05) | (0.45) |
| Weighted Avg Shares | 19.53M | 23.82M | 25.51M | 28.48M | 66.14M |
| Weighted Avg Shares (Diluted) | 19.53M | 23.82M | 25.51M | 28.48M | 66.14M |
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
Intrinsic Alpha fair value
Locked
Current Price
$0.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.